Why the study?
CAD management has become increasingly complex with rapidly evolving therapies, creating a sheer volume of occasionally contradictory clinical trial data that can cause confusion.
Answers are grounded in this paper and cite their sources.
This review highlights the importance of individualized, shared decision-making in choosing between medical therapy, PCI, and CABG for CAD management.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Amponsah et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: